MedTrace Logo

MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

NCT02673021 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-10-04

No results posted yet for this study

Summary

Does lung ablation improve clinical outcomes for patients deemed to be surgically high-risk?

Conditions

  • Lung Neoplasms
  • Cancer of Lung
  • Cancer of the Lung
  • Lung Cancer
  • Neoplasms, Lung
  • Neoplasms, Pulmonary
  • Pulmonary Cancer
  • Pulmonary Neoplasms
  • Metastatic Cancer to the Lung

Interventions

PROCEDURE

Microwave ablation

Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.

Sponsors & Collaborators

  • Medtronic - MITG

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Shanda Blackmon, MD, MPH · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-08
Primary Completion
2020-03-13
Completion
2020-03-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673021 on ClinicalTrials.gov